CAJ | 학술논문

目的：探讨激素补充治疗药物雌二醇屈螺酮片对绝经期女性骨密度和骨代谢的影响。方法选取2012年3月—2013年6月在海军总医院就诊并采用雌二醇屈螺酮片治疗绝经期症状的45～60（52．5±3．4）岁女性，并于治疗3个月及6个月时进行随访，对治疗前后患者的骨密度和骨代谢指标进行观察。结果共64例入组并完成随访。治疗后患者绝经症状较治疗前明显缓解。治疗6个月后腰椎及髋部大粗隆的骨密度较治疗前明显升高[治疗6个月时分别为（1．0250±0．0191） g／cm2、（0．4847±0．1380） g／cm2，治疗前分别为（1．0167±0．1046） g／cm2、（0．4555±0．0899） g／cm2]，差异均有统计学意义（P＜0．05）。治疗后骨代谢标志物骨碱性磷酸酶和抗酒石酸酸性磷酸酶较治疗前明显下降[治疗前分别为（65．82±14．75） U／L和（6．15±3．02） U／L，治疗3个月时分别为（61．14±12．38） U／L和（5．99±2．98） U／L，治疗6个月时分别为（58．77±11．35） U／L和（4．90±2．90） U／L]，差异均有统计学意义（P＜0．05）。结论雌二醇屈螺酮片能有效缓解绝经后女性的骨密度和骨代谢指标，有助于绝经后女性骨质疏松性骨折的预防。
목적：탐토격소보충치료약물자이순굴라동편대절경기녀성골밀도화골대사적영향。방법선취2012년3월—2013년6월재해군총의원취진병채용자이순굴라동편치료절경기증상적45～60（52．5±3．4）세녀성，병우치료3개월급6개월시진행수방，대치료전후환자적골밀도화골대사지표진행관찰。결과공64례입조병완성수방。치료후환자절경증상교치료전명현완해。치료6개월후요추급관부대조륭적골밀도교치료전명현승고[치료6개월시분별위（1．0250±0．0191） g／cm2、（0．4847±0．1380） g／cm2，치료전분별위（1．0167±0．1046） g／cm2、（0．4555±0．0899） g／cm2]，차이균유통계학의의（P＜0．05）。치료후골대사표지물골감성린산매화항주석산산성린산매교치료전명현하강[치료전분별위（65．82±14．75） U／L화（6．15±3．02） U／L，치료3개월시분별위（61．14±12．38） U／L화（5．99±2．98） U／L，치료6개월시분별위（58．77±11．35） U／L화（4．90±2．90） U／L]，차이균유통계학의의（P＜0．05）。결론자이순굴라동편능유효완해절경후녀성적골밀도화골대사지표，유조우절경후녀성골질소송성골절적예방。
Objective To investigate the effects of estradiol and drospirenone tablets ( E2/DRSP) on bone mineral density and bone turnover markers.Methods This was a prospective, self-controlled cohort study.Postmenopausal women who were treated with E2/DRSP for at least 6 months from March 2012 to June 2013 and at the age of 45—60 (52.5±3.4) years were enrolled. Comparisons were made by bone mineral density and bone turnover markers ( bone alkaline phospha-tase and tartrate-resistant acid phosphatase) between pre-and post-treatment.Results A total of 64 women were enrolled.Symptoms of menopausal syndrome alleviated significantly.Bone mineral den-sities of the lumber spine [(1.016 7±0.104 6) g/cm2 vs (1.025 0±0.019 1) g/cm2] and the hip [(0.455 5±0.089 9) g/cm2 vs (0.484 7±0.138 0) g/cm2] were significantly improved after 6 months of treatment ( P<0.05 ) .Levels of bone alkaline phosphatase [ ( 65.82 ±14.75 ) U/L at baseline vs (61.14±12.38) U/L, (58.77±11.35) U/L at 3rd and 6th month, respectively, P<0.05] and tartrate-resistant acid phosphatase [(6.15±3.02) U/L at baseline vs (5.99±2.98) U/L, (4.90±2.90) U/L at 3rd and 6th month, respectively, P<0.05)] were significantly decreased after treatment of E2/DRSP .Conclusion E2/DRSP can alleviate symptoms of menopausal syn-drome effectively, and also has benefits for bone mineral density and bone metabolism.